^
Association details:
| Biomarker: | IL6 elevation |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Cyramza (ramucirumab) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
104P - Angiogenesis-related factors and clinical outcomes in combination therapy with paclitaxel (PTX), ramucirumab (RAM) plus nivolumab (Nivo) for advanced gastric cancer (AGC)
Published date:
09/14/2020
Excerpt:
...high levels of IL-8 and sICAM-1 at baseline were significantly associated with shorter OS [HR 2.69 (95%CI 1.28-5.92), p = 0.009; HR 3.50 (95%CI 1.63-8.16), p = 0.001, respectively]; whereas, comparable PFS....This study identified baseline plasma levels of IL-8 and sVCAM-1 as potential prognostic markers corresponding to favorable OS for combination therapy of PTX, RAM plus Nivo in patients with AGC. In addition, the increase in IL-6 level at 4 weeks may predict clinical benefit from the combination therapy.
Secondary therapy:
paclitaxel
